Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body.
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer.
This study compares radiographic progression free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib plus enzalutamide versus enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Donate to Gateway for Cancer Research
Make a difference in the fight against cancer by donating to cancer research
Gateway for Cancer Research is a 501(c)(3) non-profit organization. Tax-ID: 73-1386920